Skip to main content
NCBI home page
Biomolecules & Therapeutics logoLink to Biomolecules & Therapeutics
. 2016 Nov 8;25(3):231–238. doi: 10.4062/biomolther.2016.042

Altered Translational Control of Fragile X Mental Retardation Protein on Myelin Proteins in Neuropsychiatric Disorders

Se Jin Jeon 1, Jong Hoon Ryu 1,*, Geon Ho Bahn 2,*
PMCID: PMC5424632  PMID: 27829268

Abstract

Myelin is a specialized structure of the nervous system that both enhances electrical conductance and insulates neurons from external risk factors. In the central nervous system, polarized oligodendrocytes form myelin by wrapping processes in a spiral pattern around neuronal axons through myelin-related gene regulation. Since these events occur at a distance from the cell body, post-transcriptional control of gene expression has strategic advantage to fine-tune the overall regulation of protein contents in situ. Therefore, many research interests have been focused to identify RNA binding proteins and their regulatory mechanism in myelinating compartments. Fragile X mental retardation protein (FMRP) is one such RNA binding protein, regulating its target expression by translational control. Although the majority of works on FMRP have been performed in neurons, it is also found in the developing or mature glial cells including oligodendrocytes, where its function is not well understood. Here, we will review evidences suggesting abnormal translational regulation of myelin proteins with accompanying white matter problem and neurological deficits in fragile X syndrome, which can have wider mechanistic and pathological implication in many other neurological and psychiatric disorders.

Keywords: Myelin, Fragile X mental retardation protein, Translational control, Oligodendrocyte

INTRODUCTION

Fragile X syndrome (FXS) is a monogenic disorder that arises from abnormal expansion of a CGG repeat (> 200 CGG repeats) in the 5′-untranslated region (UTR) of the X-linked FMR1 gene, leading to loss of fragile X mental retardation protein (FMRP) expression (Saldarriaga et al., 2014; Chen and Joseph, 2015). FMRP is an RNA-binding protein, which binds to almost 4% of brain transcripts to regulate mRNA transport, translation, and stability. FMRP is known to inhibit mRNA translation and its absence results in the elevated translation of intracellular signaling components, such as group 1 metabotropic glutamate receptors (mGluR), which results in the defects of ERK1/2 and PI3K-AkT-mTOR intracellular signaling pathways (Richter et al., 2015). These findings suggest that loss of FMRP leads to general deficits in the efficiency and regulation of cellular signaling, dysfunctions that might be common to psychiatric disorders. Indeed, FXS patients often show comorbid psychiatric symptoms, such as cognitive deficit, communication problem, attention deficit, and aggression (Tranfaglia, 2011, 2012). Likewise, most FXS patients have been diagnosed with mood disorder, attention-deficit hyperactivity disorder (ADHD), autism, anxiety, and depression (Tranfaglia, 2011). In case of fragile X-associated tremor/ataxia syndrome (FXTAS), another genetic variant with CGG repeat in 5′-UTR within FMR1 gene (55–200 CGG repeats), mRNA gain-of-function toxic effects result in a neurodegenerative condition (Hagerman and Hagerman, 2015). Major features of FXTAS are inattention, tremor or ataxia with an increase in incidence and prevalence with age (Brown and Stanfield, 2015; Hagerman and Hagerman, 2015). In addition, white matter intensities are affected in FXTAS patients, with symptoms like Parkinsonism, cognitive decline, memory problems, autonomic dysfunction, and neuropathy (Brown and Stanfield, 2015). Nevertheless, the association between white matter dysfunction and FMRP-related psychiatric or neurologic dysfunction, not to mention its mechanism of action, is unclear yet.

White matter is the brain region underlying the gray matter, composed of neuronal fibers coated with electrical insulation called myelin (Fields, 2008). Myelin is a multilayered, lipid-rich coating of axons, which enhances the conduction velocity of nerve impulses, contributes to compact nervous systems, and reduces metabolic costs of neural activity (Fields, 2008; Haroutunian et al., 2014). Myelination continuously occurs for decades in human brain and is modifiable by experience. In addition, myelin affects information processing by regulating conduction velocity. Recent post mortem studies have revealed structural differences in white matter tracts related to a wide range of neurological and psychiatric illnesses, including ADHD, depression, bipolar disorder, language problem, autism, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive decline, Alzheimer’s disease, Tourette’s disorder, and schizophrenia (Haroutunian et al., 2014; Mighdoll et al., 2015). An important issue is whether these changes in myelin gene expression or white matter structure are a direct cause of the psychiatric disorders or secondary consequences of abnormal brain function on white matter. However, the altered expression of myelin-associated genes in several neuropsychiatric disorders implies that white matter malfunction may contribute to the neurological and psychiatric illnesses (Mighdoll et al., 2015; Voineskos, 2015). For example, experimental manipulation of oligodendrocytes gene expression regulates glial development and myelination and causes behavioral changes mimicking schizophrenia (Ren et al., 2013). Obviously they are regulated by transcriptional control, but some of these genes are also regulated (targeted) translationally by several mechanisms one of which involves RNA binding proteins such as FMRP. Therefore, the identification, characterization and modulation of the RNA targets of FMRP will provide novel clues about the pathophysiological mechanism of human (psychiatric) disorders affected by white matter dysfunction.

MYELIN AND ITS FUNCTION

Myelin is a specialized membrane which spirally ensheathes axons by oligodendrocytes and Schwann cells of the central nervous system (CNS) and the peripheral nervous system (PNS), respectively (Fields, 2008; Nave and Werner, 2014). Myelination is one of the most pivotal cell-cell interactions for normal brain development, involving extensive information exchange such as motor, sensory, and higher-order cognitive function between differentiating oligodendrocytes and axons (Nave and Werner, 2014). By wrapping the nervous axons, the membrane sheath facilitates fast conduction of the action potential and maintains the integrity of axons. For example, conduction velocity of myelinated axons is quickened up to 150 m/s, whereas that of non-myelinated axons ranges from 0.5 to 10 m/s (Toritsuka et al., 2015). Thus, myelin is required for proper connectivity during neural development and for electrical activity and maintenance of mature neurons. Myelination in the brain is multi-stage process (Nave and Werner, 2014). First, oligodendrocytes must be differentiated from their pluripotent precursors. This step involves a crosstalk among multiple transcription factors that restricts the developmental potential of the cell. Second, the precursor cells must migrate to the site of myelination, which requires communication between the migrating cells and the axons they are destined to form. Third, transcriptional and post-transcriptional changes force it to release from the cell cycle and differentiate into a mature oligodendrocyte. Last, processes extended from the mature cells wrap around the target axon and prepare to form the mature myelin structure. Considering the morphological complexities of oligodendrocytes, they necessitate the strategies to control gene expression at regions distal to the cell body. These strategies could influence how the cell decides where to migrate, when to stop dividing and differentiate, and which axons to myelinate (wrap). In addition, myelin formation requires the oligodendrocyte to regulate gene expression in response to changes in its extracellular environment. Because these changes occur at a distance from the cell body, post-transcriptional control of gene expression allows the cell to fine-tune its response (Zearfoss et al., 2008). So fine control of genetic and epigenetic interplay during oligodendrocyte maturation and myelination formation is crucial for proper neural connectivity and higher brain functions.

DYSREGULATED MYELINATION AND PSYCHIATRIC DISORDERS

Myelin can be disturbed by either damage or genetic problems (Barateiro et al., 2016). For example, several autoimmune diseases (Guillain-Barré syndrome in the PNS and multiple sclerosis in the CNS) (Kamm and Zettl, 2012), inherited disorders affecting structural genes in myelin (Charcot-Marie-Tooth disease, Dejerine-Sottas syndrome and Pelizaeus-Marzbacher disease) (Kleopa et al., 2010; Barrette et al., 2013), metabolic disorders (Canavan, Menke’s, Krabbe’s and Refsum’s disease) (Kumar et al., 2006), infection, trauma, toxins (including alcohol or drugs), hormonal imbalance and asphyxia are the cause of such dysfunction (Kohlhauser et al., 2000). Additionally, astrocyte-related diseases like Alexander disease result in severe hypomyelination, mental retardation and death (Ettle et al., 2016).

Numerous psychiatric disorders, including schizophrenia, depression, bipolar disorder, obsessive-compulsive disorder and posttraumatic stress disorder, and neurodevelopmental disorders such as autism and ADHD have recently been associated with white matter defects evidenced by brain imaging and histological analysis of post mortem tissues (Onnink et al., 2015). Brain imaging methods show volumetric and microstructural white matter changes as well as differences in functional connectivity, biochemical changes in white matter or alterations in white matter tracts or myelin genes between normal and patient (Rowley et al., 2015). For instance, an analysis of 6000 genes in prefrontal cortex of schizophrenia brains, 89 genes were abnormally regulated, of these 35 were genes involved in myelination (Hakak et al., 2001). This includes genes encoding myelin-associated glycoprotein (MAG), myelin and lymphocyte protein (MAL), MBP, myelin proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG) and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP), peripheral myelin protein 22 (PMP22); growth factors and receptors ErbB3, NRG1 and BDNF; transcription factors Sox10, Olig 1 and Olig 2; and other genes associated with oligodendroctye development and myelination, including QKI and Claudin11. In addition, genetic abnormalities resulting in demyelination have been implicated in psychiatric disorders (Voineskos, 2015). Polymorphisms of several genes including MAG, CNP, MOG, NRG1 and Olig 2 are susceptible to numerous psychiatric disorders. Taken together, dysregulation of myelination and manifestation of psychiatric disorders are closely related and affected by common genetic factors, implying understanding the mechanism of their expression may provide hints for the development of better diagnostic and therapeutic options.

FMRP AND FXS

Fragile X mental retardation protein (FMRP) is a genetic product of FMR1 gene. FMRP, most commonly found in the brain, is essential for normal cognitive development and female reproductive function (Lozano et al., 2014). Mutations of this gene can lead to fragile X syndrome (FXS), FXTAS, mental retardation, premature ovarian failure, autism, Parkinson’s disease, developmental delays and other cognitive deficits. FMRP harbors two k-homology (KH) domains and one argi-nine-glycine repeated (RGG box) domain and binds to RNA. As an RNA binding protein, FMRP regulates bound mRNA stability, translation, and transport to modulate physiological functions within brain (Chen and Joseph, 2015). As discussed above, 90% of FXS patients show comorbid conditions including ADHD, autism, depression, and aggression. 85% is connected with intellectual disability, 41% of patients shows a mood disorders among them, 70% and 12% presents anxiety and depression, respectively (Scharf et al., 2015). FXTAS patients also show a spectrum of symptoms such as tremor, motor dysfunction and cognitive deficit (Lozano et al., 2014). As shown in recent clinical study, FXTAS had slower nerve conduction velocities, prolonged F-wave latencies, and slower compound muscle action potential amplitudes compared with controls and unaffected permutation males (Soontarapornchai et al., 2008). Collectively, there was a significant relationship between the number of CGG repeat and reduction of nerve conduction velocity. The significant relationship also applies between elevated messenger RNA levels of FMR1 and reduction of the muscle action potential velocity in the permutation group, suggesting that the FMR1 gene is a causal factor.

MYELINATION DEFECT IN FXS: ABNORMAL MYELIN-RELATED GENE EXPRESSION IN FXS

Recently, several groups reported that FMRP is expressed in MBP-positive oligodendrocytes of rodents and human (Giampetruzzi et al., 2013; Pacey et al., 2013) as well as oligodendrocyte lineage cells in differentiation stage-specific manner (Wang et al., 2004), raising the possibility that FMRP regulates some aspects of myelination processes. Lack of FMRP in FXS could lead to premature myelination or myelin abnormalities. Several groups reported that FMRP binds myelin basic protein (MBP) mRNA, one of major myelination proteins, both in vivo and in vitro and inhibits MBP mRNA translation in vitro (Li et al., 2001; Wang et al., 2004; Darnell et al., 2011; Giampetruzzi et al., 2013). In addition, FMRP expression decrease during oligodendrocyte maturation either in vivo or in culture (Giampetruzzi et al., 2013), suggesting that FMRP represses translation of MBP mRNA in immature oligodendrocytes and later allows translation of MBP mRNA in mature oligodendrocytes concomitant with the decreased FMRP expression (Wang et al., 2004). Pacey et al. (2013) showed that Fmr1 knockout mice display abnormalities in the myelination of cerebellar axons as early as the first postnatal week, corresponding to the equivalent time in human brain development when FXS symptoms become apparent. At postnatal day (PND) 7, diffusion tensor magnetic resonance imaging showed an 80–85% reduction of MBP expression, fewer and thinner myelination in Fmr1 knockout mouse cerebellum compared with wild-type mice (Giampetruzzi et al., 2013; Pacey et al., 2013). This altered expression was recovered to the normal levels at PND 30, suggesting that impaired maturation or function of oligodendrocyte precursor cells induces delayed myelination in the Fmr1 knockout mouse brain (Pacey et al., 2013). Taken together, white matter abnormalities in early brain development represent an underlying neurological deficit in FXS and other neuropsychiatric disorders.

TRANSLATIONAL CONTROL OF mRNAs IN OLIGODENDROCYTES

Polarization and functional compartmentalization of cells necessitate the specific transport and localization of mRNAs. Local and specific translation of a subset of these mRNAs can allow rapid responses to stimulation. Since oligodendrocyte processes trap onto the several axons at the same time, an appropriate regulation of rapid protein induction only at the site of activation is crucial for performing and maintaining proper myelin function. Local regulation of protein synthesis represents one mechanism used to control the different requirements for myelin sheath at each axo-glia interaction (Laursen et al., 2011). Supporting to this hypothesis, polyribosomes as well as a number of myelin-related mRNAs are observed in distal oligodendrocyte processes, sometimes in proximity to the forming myelin sheaths (Barbarese et al., 1995). Colman confirmed the distribution of newly synthesized myelin proteins from rats after an intracranial injection of 35S-methionine (Colman et al., 1982). MBP, one of myelin-forming proteins, was rapidly induced in the myelin sheath, and was not detected in rough microsome, suggesting direct synthesis in the process. Similar results were obtained in the in vitro translational experiments (Colman et al., 1982). Both in vivo labeling and in vitro translation experiments support that MBP-synthesizing polysomes are rapidly activated in the oligodendrocyte processes.

Translational regulation of myelin-related mRNAs is also shown by inhibition of elongation inhibitor (Geva et al., 2010) or treatment of protein synthesis inhibitor (Cullen and Webster, 1989). The anomalous development of white matter in eukaryotic translation initiation factor 2B knockout mice underscores the importance of tight translational control in normal myelin formation and maintenance (Geva et al., 2010). Cycloheximide, a protein translation inhibitor, reduced the number of polyribosomes or cell processes of oligodendrocyte by reducing myelin proteins synthesis (Cullen and Webster, 1989).

The translatability of the local mRNAs may be influenced by its 3′ UTR which bound to RBPs. In neurons, the cytoplasmic polyadenylation element (CPE) within the 3′UTR is recognized by an activated CPE-binding protein (CPEB) thus triggering poly A elongation and enhancing its translation (Huang and Richter, 2007). Similar mechanism of mRNA activation could occur for pre-existing messengers in oligodendrocyte, which might be dictated by the prior transport and availability of the appropriate mRNAs in situ. Subcellularly localizing mRNAs are packaged into ribonucleoprotein (RNP) complexes that engage with motor proteins for directed transport along cytoskeletal tracks and ensure their translational silencing. These RNP complexes are mainly composed of cis-regulatory elements that are present on the mRNA and specific trans-acting factors recognizing the cis-elements. Among these trans-acting factors, conserved RNA-binding proteins control both targeting of the mRNA and translational repression. Translation of most local mRNAs including MBP is an event temporally separated from transcription and transport. In respect of energy cost, direct translation of distally localized mRNAs would be easier and economical way of regulation.

Interestingly, many of the myelin genes are targets for specific RNA binding proteins (RBP) (Zearfoss et al., 2008). Numerous RNA binding proteins are expressed in oligodendrocyte lineage (from precursor cell to mature one), and control multiple aspects of gene expression, including regulation of mRNA stability and degradation, transport, alternative splicing, and translation (Campagnoni et al., 1991). Dysregulation of such RBPs in psychiatric disorders will affect downstream RNA metabolism, which further modulates oligodendrocyte development and myelination process (Larocque and Richard, 2005).

One such target is FMRP and the remaining questions are what the molecular targets and the mechanism of the regulation are (Fig. 1).

Fig. 1.

Fig. 1.

Open in a new tab

Schematic representation of local mRNA transport and translation in oligodendrocyte processes. Under physiological condition, FMRP (violet) and target mRNA (circles) mRNP components moves into distal process in association with motor proteins such as kinesin (blue circle), which usually kept relatively dormant until the activation. When exposed to an appropriate signal, the mRNP complex dissociates RBP such as FMRP, which initiates translation of mRNA locally, resulting in the increased protein synthesis specifically in places of activation.

OLIGODENDROCYTE MOLECULAR TARGETS MODULATED BY FMRP

Oligodendrocyte-related genes

FMRP negatively regulates the translation of two myelin-related transcripts: MBP and PLP (Giampetruzzi et al., 2013). Binding assays using in vitro translated FMRP and biotin-labeled MBP and PLP mRNAs demonstrate an interaction between FMRP and these transcripts (Darnell et al., 2011). One of well-defined FMRP targets in neurons is microtubule associated protein 1B (MAP1b) (Lu et al., 2004; Darnell et al., 2011). The MAP1b knockout mouse has been reported to have myelin defects in the PNS, demonstrating its requirement for myelination (Gonzalez-Billault et al., 2002). Further study is necessary to determine whether an interaction between FMRP and the MAP1b mRNA occurs in oligodendrocyte and mediates myelination. Although the function of FMRP in oligodendrocytes has not fully investigated yet, it is notable that both MBP and MAP1b are also targets of QKI, one of RBPs. Interestingly, and the expression of MBP and MAP1b is regulated by QKI, suggesting the role of RBPs in the regulation of myelin function (Wu et al., 2001; Larocque et al., 2002). It is therefore possible that the two RNA binding proteins, i.e. FMRP and QKI could coordinate expression of target proteins for appropriate control of myelin function. FMRP silences translation of the RNAs in precursors, while QKI would stabilize the RNAs and lead to increased expression of target mRNAs during myelination. As FMRP is a KH and RGG box RNA binding protein, many studies have been conducted to find its targets (Darnell et al., 2011; Chen and Joseph, 2015). FMRP RGG box binds an RNA motif known as a G-quartet, identified by SELEX (Chen et al., 2003). Most recently, SELEX experiments carried out using the FMRP KH domain demonstrate that the KH domain recognizes a complicated tertiary RNA structure called a kissing complex (Chen et al., 2003). Below, we will further discuss previously reported FMRP targets, which might be related to oligodendrocyte progression and myelination (Table 1).

Table 1.

Myelination-related genes regulated by FMRP expression

Class Molecules Myelin-function References
Transcription regulators Tcf7l2/Tcf4 Myelination decrease/increase Fancy et al., 2009
Sox4, Sox5, Sox6, Sox8, Sox9, Sox10, Sox11, Sox17 Myelination decrease/increase Oligodendrocyte pool Stolt et al., 2006, Stolt and Wegner, 2010
Nuclear hormone receptor Myelination increase Pombo et al., 1999
Nkx2.2 Myelination decrease/increase Qi et al., 2001
Nkx6.1, NKx6.2 Myelination increase Oligodendrocyte maturation Wei et al., 2005
Open in a new tab

Transcription factors

Numerous transcription factors are involved in the functional regulation of myelination-mediating glia (Emery, 2010). The list includes Nkx6.2 (Gtx), POU domain protein Tst-1/Oct-6, Brn-1/2, MyTI (Myelin transcription factor I), new Cys2/His2 zinc finger proteins rKR1/2, Krox-24 (Egr-1, Zif286), and Sox family. These transcription factors work together in sequential manner to induce and complete fine-tuning of myelination structures. Among these known factors, sox family transcription factors, Nkx6.2, and Brn-1/2 are reported as FMRP targets (Kunde et al., 2011).

Sox family transcription factors are well-established regulators of cell fate decisions during development. Sox family maintains precursor or stem cell properties (undifferentiated state) and prevents differentiation promoting proteins from acting normally. By interaction of cognate mRNAs with FMRP, Sox family expression is repressed, which may inhibit neural differentiation (Telias et al., 2015). In addition, when FMRP expression is abolished as shown in FXS, altered neurogenesis and increased neuronal differentiation is observed (Luo et al., 2010). It should be determined whether FMRP-mediated regulation of Sox transcription factor expression affects oligodendrocyte pool size as well. Recent studies have also suggested that Nkx6.2/Gtx homeodomain transcription factors are involved in the regulation of oligodendrocyte maturation and myelination, which occur predominantly in postnatal stages (Cai et al., 2010). Nkx6.2 is initially expressed in differentiating oligodendrocyte precursor cells but quickly downregulated as oligodendrocyte precursor cells undergo terminal differentiation (Cai et al., 2010). Intriguingly, Nkx6.2 expression is upregulated in mature myelinating oligodendrocytes at later stages. Although data demonstrating direct interaction of FMRP with Nkx6.2 mRNA is unavailable yet, Nkx6.2 and FMRP is coincidently expressed in the oligodendrocyte developmental tract and microarray data revealed the interaction between them, which warrants further investigation to uncover the link.

Brain-2 (Brn-2), a Class III POU transcription factor, plays function largely overlapping with that of Oct-6 in driving the transition from promyelinating to myelinating cells (Friedrich et al., 2005). Miyashiro et al. showed the possible interaction of FMRP and Brn-2, which was later reproduced by other groups using photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) assay (Miyashiro et al., 2003; Darnell et al., 2011). Largely devoted to the study of neuronal development (Patel et al., 2014; Contractor et al., 2015), investigating the role of FMRP on the regulation of oligodendrocyte development will pave the new way to understand the complex process.

micro RNAs

Recently, micro RNAs (miRNA) have emerged as important regulators of gene expression in oligodendrocyte (Svaren, 2014). FMRP can regulate miRNA pathway through interaction with miRNA biogenesis components or through direct association with miRNAs (Jin et al., 2004). The interaction between miRNA and FMRP would mediate miRNA-dependent repression of translation through the RNA interference pathway, by interacting with the components of the RNA-induced silencing complex (RISC) (Jin et al., 2004). Several defined miRNAs described below have been reported as potential FMRP targets (Yi et al., 2010) (Table 2).

Table 2.

Micro RNAs targets of FMRP

miRNA Myelin-function References
miR 124 Myelination decrease by Sox9 inhibition Morris et al., 2015
miR 138 Myelination decrease by Notch inhibition Lau et al., 2008
miR 144 Myelination increase by Enp6 inhibition Svaren, 2014
miR 219 Myelination decrease by Sox2/Hes5 inhibition Zhao et al., 2010
miR 338 Myelination decrease by Sox2/Hes5 inhibition Zhao et al., 2010
Open in a new tab

Micro RNA-219 (miR-219) relatively specific to oligodendrocytes within the CNS, is induced along with oligodendrocyte differentiation (Zhao et al., 2010). Target mRNAs of miR-219 are Sox6, Hes5, PDGFR alpha, ZFP238, FoxJ3, Evolv7, and ENPP6 (Zhao et al., 2010; Svaren, 2014), which enhance the oligodendrocyte differentiation by inhibiting pro-proliferation transcription factors. Indeed, knockdown of miRNA-219 blocks oligodendrocyte differentiation in vivo as well as in vitro (Zhao et al., 2010). Additionally, its expression is downregulated in the CNS following deletion of dicer in oligodendrocytes (Dugas et al., 2010), suggesting its crucial role for differentiation. Recent research has identified miR-219 as a key molecule in the behavioral manifestations associated with pathophysiology of schizophrenia (Kocerha et al., 2009), which is related to the abnormal FMRP-dependent Sox expression. Another potential FMRP target is miRNA-338 (Yi et al., 2010), which is relatively specific to oligodendrocytes and induced with oligodendrocyte differentiation. Its target includes Sox6 and Hes5, which explains why knockdown of miRNA-338 blocks oligodendrocyte differentiation (Zhao et al., 2010). Micro RNA-138 is transiently induced at early stage of oligodendrocyte differentiation. In FMRP knockout studies, the role of miR-138 in synaptic development and dendritic arborization is revealed (Bicker et al., 2014). In vivo experiments in the mouse subventricular zone (SVZ) have demonstrated that miR-138 down-regulates Sox9 and thereby inhibits precursor division and stimulates differentiation. Overall, miR-138 appears to play a major role in oligodendrocyte differentiation by down-regulating genes essential for precursor proliferation, while stimulating oligodendrocyte-specific genes and cytoskeletal rearrangements. Similar to miRNA-219, micro RNA-144 is down-regulated following the deletion of dicer in oligodendrocytes. Its target mRNA includes Enp6 (Svaren, 2014). Previously, miR-144 is reported to be involved in neurite outgrowth, neurogenesis, signaling of PTEN, ERK, and Wnt/beta-catenin pathways (Zhou et al., 2009; Tawk et al., 2011). Interestingly, Edbauer et al. (2010) showed that miR-124 and miR-144, as well as several other miRNAs, are associated with FMRP in mouse brain. FMRP controls pre-miR-144 processing into mature miR-144. Since miR-144 stimulates oligodendrocyte differentiation, its association with FMRP will suggest its role in FXS pathology including abnormal myelination.

CONCLUSIONS

In FXS patients or knockout mice studies, many behavioral and neuroanatomical problems show comorbidity symptoms observed in psychiatric disorders. The most prevalent symptoms are cognitive decline, mood problem, mental retardation, and lipid metabolism abnormality, which have some association with the reduction in oligodendrocyte pool or delayed myelin formation. The common pathophysiological mechanism is abnormal regulation of gene expression either transcriptionally or post-transcriptionally, which further impairs myelin forming process such as altered oligodendrocyte population or dysregulated myelin component and structure, leading to a malfunction problem. In fact, FMRP knockout rodents still showed behavioral and synaptic problems even after their recovery from white matter abnormality in later period, demonstrating fine tuning and cooperative in-time transcriptional and post-transcriptional regulation are important for appropriate oligodendrocyte development and myelin function. Collectively, integration of findings in recent studies at multiple levels of research have allowed a deeper understanding of myelination defects and neuropsychiatric behaviors, identifying the functional role of FMRP in this process, which provide additional targets for therapeutic intervention.

Acknowledgments

This study was supported by grants of the Basic Science Research Program through the NRF funded by the Ministry of Education (NRF-2014R1A1A2059179) and by the Korean Health Technology R&D Project, Ministry of health & welfare, Republic of Korea (No. HI12C0021).

Footnotes

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

REFERENCES

  1. Barateiro A, Brites D, Fernandes A. Oligodendrocyte development and myelination in neurodevelopment: molecular mechanisms in health and disease. Curr Pharm Des. 2016;22:656–679. doi: 10.2174/1381612822666151204000636. [DOI] [PubMed] [Google Scholar]
  2. Barbarese E, Koppel DE, Deutscher MP, Smith CL, Ainger K, Morgan F, Carson JH. Protein translation components are colocalized in granules in oligodendrocytes. J Cell Sci. 1995;108:2781–2790. doi: 10.1242/jcs.108.8.2781. [DOI] [PubMed] [Google Scholar]
  3. Barrette B, Nave KA, Edgar JM. Molecular triggers of neuroinflammation in mouse models of demyelinating diseases. Biol Chem. 2013;394:1571–1581. doi: 10.1515/hsz-2013-0219. [DOI] [PubMed] [Google Scholar]
  4. Bicker S, Lackinger M, Weiss K, Schratt G. MicroRNA-132, -134, and -138: a microRNA troika rules in neuronal dendrites. Cell Mol Life Sci. 2014;71:3987–4005. doi: 10.1007/s00018-014-1671-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown SS, Stanfield AC. Fragile X premutation carriers: A systematic review of neuroimaging findings. J Neurol Sci. 2015;352:19–28. doi: 10.1016/j.jns.2015.03.031. [DOI] [PubMed] [Google Scholar]
  6. Cai J, Zhu Q, Zheng K, Li H, Qi Y, Cao Q, Qiu M. Co-localization of Nkx6.2 and Nkx2.2 homeodomain proteins in differentiated myelinating oligodendrocytes. Glia. 2010;58:458–468. doi: 10.1002/glia.20937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Campagnoni AT, Verdi JM, Verity AN, Amur-Umarjee S, Byravan S. Posttranscriptional regulation of myelin protein gene expression. Ann N Y Acad Sci. 1991;633:178–188. doi: 10.1111/j.1749-6632.1991.tb15608.x. [DOI] [PubMed] [Google Scholar]
  8. Chen E, Joseph S. Fragile X mental retardation protein: a paradigm for translational control by RNA-binding proteins. Biochimie. 2015;114:147–154. doi: 10.1016/j.biochi.2015.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience. 2003;120:1005–1017. doi: 10.1016/S0306-4522(03)00406-8. [DOI] [PubMed] [Google Scholar]
  10. Colman DR, Kreibich G, Frey AB, Sabatini DD. Synthesis and incorporation of myelin polypeptides into CNS myelin. J Cell Biol. 1982;95:598–608. doi: 10.1083/jcb.95.2.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Contractor A, Klyachko VA, Portera-Cailliau C. Altered neuronal and circuit excitability in fragile X syndrome. Neuron. 2015;87:699–715. doi: 10.1016/j.neuron.2015.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cullen MJ, Webster HD. Inhibition of protein synthesis during CNS myelination produces focal accumulations of membrane vesicles in oligodendrocytes. J Neurocytol. 1989;18:763–774. doi: 10.1007/BF01187229. [DOI] [PubMed] [Google Scholar]
  13. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247–261. doi: 10.1016/j.cell.2011.06.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dugas JC, Cuellar TL, Scholze A, Ason B, Ibrahim A, Emery B, Zamanian JL, Foo LC, McManus MT, Barres BA. Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination. Neuron. 2010;65:597–611. doi: 10.1016/j.neuron.2010.01.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, Kaing S, Sanai N, Franklin RJ, Rowitch DH. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 2009;23:1571–1585. doi: 10.1101/gad.1806309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron. 2010;65:373–384. doi: 10.1016/j.neuron.2010.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Emery B. Regulation of oligodendrocyte differentiation and myelination. Science. 2010;330:779–782. doi: 10.1126/science.1190927. [DOI] [PubMed] [Google Scholar]
  18. Ettle B, Schlachetzki JC, Winkler J. Oligodendroglia and myelin in neurodegenerative diseases: more than just bystanders? Mol Neurobiol. 2016;53:3046–3062. doi: 10.1007/s12035-015-9205-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008;31:361–370. doi: 10.1016/j.tins.2008.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Friedrich RP, Schlierf B, Tamm ER, Bosl MR, Wegner M. The class III POU domain protein Brn-1 can fully replace the related Oct-6 during schwann cell development and myelination. Mol Cell Biol. 2005;25:1821–1829. doi: 10.1128/MCB.25.5.1821-1829.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Geva M, Cabilly Y, Assaf Y, Mindroul N, Marom L, Raini G, Pinchasi D, Elroy-Stein O. A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter. Brain. 2010;133:2448–2461. doi: 10.1093/brain/awq180. [DOI] [PubMed] [Google Scholar]
  22. Giampetruzzi A, Carson JH, Barbarese E. FMRP and myelin protein expression in oligodendrocytes. Mol Cell Neurosci. 2013;56:333–341. doi: 10.1016/j.mcn.2013.07.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gonzalez-Billault C, Owen R, Gordon-Weeks PR, Avila J. Microtubule-associated protein 1B is involved in the initial stages of axonogenesis in peripheral nervous system cultured neurons. Brain Res. 2002;943:56–67. doi: 10.1016/S0006-8993(02)02534-9. [DOI] [PubMed] [Google Scholar]
  24. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome. Ann N Y Acad Sci. 2015;1338:58–70. doi: 10.1111/nyas.12693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA. 2001;98:4746–4751. doi: 10.1073/pnas.081071198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Haroutunian V, Katsel P, Roussos P, Davis KL, Altshuler LL, Bartzokis G. Myelination, oligodendrocytes, and serious mental illness. Glia. 2014;62:1856–1877. doi: 10.1002/glia.22716. [DOI] [PubMed] [Google Scholar]
  27. Huang YS, Richter JD. Analysis of mRNA translation in cultured hippocampal neurons. Meth Enzymol. 2007;431:143–162. doi: 10.1016/S0076-6879(07)31008-2. [DOI] [PubMed] [Google Scholar]
  28. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, Nelson DL, Moses K, Warren ST. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci. 2004;7:113–117. doi: 10.1038/nn1174. [DOI] [PubMed] [Google Scholar]
  29. Kamm C, Zettl UK. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev. 2012;11:196–202. doi: 10.1016/j.autrev.2011.05.012. [DOI] [PubMed] [Google Scholar]
  30. Kleopa KA, Orthmann-Murphy J, Sargiannidou I. Gap junction disorders of myelinating cells. Rev Neurosci. 2010;21:397–419. doi: 10.1515/REVNEURO.2010.21.5.397. [DOI] [PubMed] [Google Scholar]
  31. Kocerha J, Faghihi MA, Lopez-Toledano MA, Huang J, Ramsey AJ, Caron MG, Sales N, Willoughby D, Elmen J, Hansen HF, Orum H, Kauppinen S, Kenny PJ, Wahlestedt C. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci USA. 2009;106:3507–3512. doi: 10.1073/pnas.0805854106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kohlhauser C, Mosgoller W, Hoger H, Lubec B. Myelination deficits in brain of rats following perinatal asphyxia. Life Sci. 2000;67:2355–2368. doi: 10.1016/S0024-3205(00)00816-X. [DOI] [PubMed] [Google Scholar]
  33. Kumar S, Mattan NS, de Vellis J. Canavan disease: a white matter disorder. Ment Retard Dev Disabil Res Rev. 2006;12:157–165. doi: 10.1002/mrdd.20108. [DOI] [PubMed] [Google Scholar]
  34. Kunde SA, Musante L, Grimme A, Fischer U, Muller E, Wanker EE, Kalscheuer VM. The X-chromosome-linked intellectual disability protein PQBP1 is a component of neuronal RNA granules and regulates the appearance of stress granules. Hum Mol Genet. 2011;20:4916–4931. doi: 10.1093/hmg/ddr430. [DOI] [PubMed] [Google Scholar]
  35. Larocque D, Pilotte J, Chen T, Cloutier F, Massie B, Pedraza L, Couture R, Lasko P, Almazan G, Richard S. Nuclear retention of MBP mRNAs in the quaking viable mice. Neuron. 2002;36:815–829. doi: 10.1016/S0896-6273(02)01055-3. [DOI] [PubMed] [Google Scholar]
  36. Larocque D, Richard S. QUAKING KH domain proteins as regulators of glial cell fate and myelination. RNA Biol. 2005;2:37–40. doi: 10.4161/rna.2.2.1603. [DOI] [PubMed] [Google Scholar]
  37. Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD. Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci. 2008;28:11720–11730. doi: 10.1523/JNEUROSCI.1932-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Laursen LS, Chan CW, Ffrench-Constant C. Translation of myelin basic protein mRNA in oligodendrocytes is regulated by integrin activation and hnRNP-K. J Cell Biol. 2011;192:797–811. doi: 10.1083/jcb.201007014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 2001;29:2276–2283. doi: 10.1093/nar/29.11.2276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Lozano R, Rosero CA, Hagerman RJ. Fragile X spectrum disorders. Intractable Rare Dis Res. 2014;3:134–146. doi: 10.5582/irdr.2014.01022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lu R, Wang H, Liang Z, Ku L, O’Donnell WT, Li W, Warren ST, Feng Y. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci USA. 2004;101:15201–15206. doi: 10.1073/pnas.0404995101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Luo Y, Shan G, Guo W, Smrt RD, Johnson EB, Li X, Pfeiffer RL, Szulwach KE, Duan R, Barkho BZ, Li W, Liu C, Jin P, Zhao X. Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet. 2010;6:e1000898. doi: 10.1371/journal.pgen.1000898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Mighdoll MI, Tao R, Kleinman JE, Hyde TM. Myelin, myelin-related disorders, and psychosis. Schizophr Res. 2015;161:85–93. doi: 10.1016/j.schres.2014.09.040. [DOI] [PubMed] [Google Scholar]
  44. Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37:417–431. doi: 10.1016/S0896-6273(03)00034-5. [DOI] [PubMed] [Google Scholar]
  45. Morris JK, Chomyk A, Song P, Parker N, Deckard S, Trapp BD, Pimplikar SW, Dutta R. Decrease in levels of the evolutionarily conserved microRNA miR-124 affects oligodendrocyte numbers in Zebrafish, Danio rerio. Invert Neurosci. 2015;15:4. doi: 10.1007/s10158-015-0180-1. [DOI] [PubMed] [Google Scholar]
  46. Nave KA, Werner HB. Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503–533. doi: 10.1146/annurev-cellbio-100913-013101. [DOI] [PubMed] [Google Scholar]
  47. Onnink AM, Zwiers MP, Hoogman M, Mostert JC, Dammers J, Kan CC, Vasquez AA, Schene AH, Buitelaar J, Franke B. Deviant white matter structure in adults with attention-deficit/hyperactivity disorder points to aberrant myelination and affects neuropsychological performance. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2015;63:14–22. doi: 10.1016/j.pnpbp.2015.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pacey LK, Xuan IC, Guan S, Sussman D, Henkelman RM, Chen Y, Thomsen C, Hampson DR. Delayed myelination in a mouse model of fragile X syndrome. Hum Mol Genet. 2013;22:3920–3930. doi: 10.1093/hmg/ddt246. [DOI] [PubMed] [Google Scholar]
  49. Patel AB, Loerwald KW, Huber KM, Gibson JR. Postsynaptic FMRP promotes the pruning of cell-to-cell connections among pyramidal neurons in the L5A neocortical network. J Neurosci. 2014;34:3413–3418. doi: 10.1523/JNEUROSCI.2921-13.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Pombo PM, Barettino D, Ibarrola N, Vega S, Rodríguez-Peña A. Stimulation of the myelin basic protein gene expression by 9-cis-retinoic acid and thyroid hormone: activation in the context of its native promoter. Brain Res Mol Brain Res. 1999;64:92–100. doi: 10.1016/S0169-328X(98)00311-8. [DOI] [PubMed] [Google Scholar]
  51. Qi Y, Cai J, Wu Y, Wu R, Lee J, Fu H, Rao M, Sussel L, Rubenstein J, Qiu M. Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development. 2001;128:2723–2733. doi: 10.1242/dev.128.14.2723. [DOI] [PubMed] [Google Scholar]
  52. Ren Y, Wang H, Xiao L. Improving myelin/oligodendrocyte-related dysfunction: a new mechanism of antipsychotics in the treatment of schizophrenia? Int J Neuropsychopharmacol. 2013;16:691–700. doi: 10.1017/S1461145712001095. [DOI] [PubMed] [Google Scholar]
  53. Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci. 2015;16:595–605. doi: 10.1038/nrn4001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rowley CD, Bazin PL, Tardif CL, Sehmbi M, Hashim E, Zaharieva N, Minuzzi L, Frey BN, Bock NA. Assessing intracortical myelin in the living human brain using myelinated cortical thickness. Front Neurosci. 2015;9:396. doi: 10.3389/fnins.2015.00396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Saldarriaga W, Tassone F, Gonzalez-Teshima LY, Forero-Forero JV, Ayala-Zapata S, Hagerman R. Fragile X syndrome. Colomb Med. 2014;45:190–198. [PMC free article] [PubMed] [Google Scholar]
  56. Scharf SH, Jaeschke G, Wettstein JG, Lindemann L. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol. 2015;20:124–134. doi: 10.1016/j.coph.2014.11.004. [DOI] [PubMed] [Google Scholar]
  57. Soontarapornchai K, Maselli R, Fenton-Farrell G, Tassone F, Hagerman PJ, Hessl D, Hagerman RJ. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol. 2008;65:495–498. doi: 10.1001/archneur.65.4.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Stolt CC, Schlierf A, Lommes P, Hillgärtner S, Werner T, Kosian T, Sock E, Kessaris N, Richardson WD, Lefebvre V, Wegner M. SoxD proteins influence multiple stages of oligodendrocyte development and modulate SoxE protein function. Dev Cell. 2006;11:697–709. doi: 10.1016/j.devcel.2006.08.011. [DOI] [PubMed] [Google Scholar]
  59. Stolt CC, Wegner M. SoxE function in vertebrate nervous system development. Int J Biochem Cell Biol. 2010;42:437–440. doi: 10.1016/j.biocel.2009.07.014. [DOI] [PubMed] [Google Scholar]
  60. Svaren J. MicroRNA and transcriptional crosstalk in myelinating glia. Neurochem Int. 2014;77:50–57. doi: 10.1016/j.neuint.2014.06.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Tawk M, Makoukji J, Belle M, Fonte C, Trousson A, Hawkins T, Li H, Ghandour S, Schumacher M, Massaad C. Wnt/beta-catenin signaling is an essential and direct driver of myelin gene expression and myelinogenesis. J Neurosci. 2011;31:3729–3742. doi: 10.1523/JNEUROSCI.4270-10.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Telias M, Mayshar Y, Amit A, Ben-Yosef D. Molecular mechanisms regulating impaired neurogenesis of fragile X syndrome human embryonic stem cells. Stem Cells Dev. 2015;24:2353–2365. doi: 10.1089/scd.2015.0220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Toritsuka M, Makinodan M, Kishimoto T. Social experience-dependent myelination: an implication for psychiatric disorders. Neural Plast. 2015;2015:465345. doi: 10.1155/2015/465345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Tranfaglia MR. The psychiatric presentation of fragile X: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci. 2011;33:337–348. doi: 10.1159/000329421. [DOI] [PubMed] [Google Scholar]
  65. Tranfaglia MR. Fragile X syndrome: a psychiatric perspective. Results Probl Cell Differ. 2012;54:281–295. doi: 10.1007/978-3-642-21649-7_16. [DOI] [PubMed] [Google Scholar]
  66. Voineskos AN. Genetic underpinnings of white matter ‘connectivity’: heritability, risk, and heterogeneity in schizophrenia. Schizophr Res. 2015;161:50–60. doi: 10.1016/j.schres.2014.03.034. [DOI] [PubMed] [Google Scholar]
  67. Wang H, Ku L, Osterhout DJ, Li W, Ahmadian A, Liang Z, Feng Y. Developmentally-programmed FMRP expression in oligodendrocytes: a potential role of FMRP in regulating translation in oligodendroglia progenitors. Hum Mol Genet. 2004;13:79–89. doi: 10.1093/hmg/ddh009. [DOI] [PubMed] [Google Scholar]
  68. Wei Q, Miskimins WK, Miskimins R. Stage-specific expression of myelin basic protein in oligodendrocytes involves Nkx2.2-mediated repression that is relieved by the Sp1 transcription factor. J Biol Chem. 2005;280:16284–16294. doi: 10.1074/jbc.M500491200. [DOI] [PubMed] [Google Scholar]
  69. Wu HY, Dawson MR, Reynolds R, Hardy RJ. Expression of QKI proteins and MAP1B identifies actively myelinating oligodendrocytes in adult rat brain. Mol Cell Neurosci. 2001;17:292–302. doi: 10.1006/mcne.2000.0941. [DOI] [PubMed] [Google Scholar]
  70. Yi YH, Sun XS, Qin JM, Zhao QH, Liao WP, Long YS. Experimental identification of microRNA targets on the 3′ untranslated region of human FMR1 gene. J. Neurosci. Methods. 2010;190:34–38. doi: 10.1016/j.jneumeth.2010.04.022. [DOI] [PubMed] [Google Scholar]
  71. Zearfoss NR, Farley BM, Ryder SP. Post-transcriptional regulation of myelin formation. Biochim. Biophys. Acta. 2008;1779:486–494. doi: 10.1016/j.bbagrm.2008.06.003. [DOI] [PubMed] [Google Scholar]
  72. Zhao X, He X, Han X, Yu Y, Ye F, Chen Y, Hoang T, Xu X, Mi QS, Xin M, Wang F, Appel B, Lu QR. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron. 2010;65:612–626. doi: 10.1016/j.neuron.2010.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, Damschroder-Williams P, Du J, Chen G, Manji HK. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology. 2009;34:1395–1405. doi: 10.1038/npp.2008.131. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biomolecules & Therapeutics are provided here courtesy of Korean Society of Applied Pharmacology

RESOURCES